Associated Papers
Phosphorylated nuclear DICER1 promotes open chromatin state and lineage plasticity of AT2 tumor cells in lung adenocarcinomas.
Reyes-Castro RA et al.
Science Advances, 2023
37494452 (PubMed )
Supplement: sciadv.adf6210_sm.pdf
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
Gill SJ et al.
Molecular Cancer Therapeutics, 2021
Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction.
Ditano JP et al.
Scientific Reports, 2021
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL et al.
Oncogene, 2020
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN et al.
British Journal of Cancer, 2018
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Smida M et al.
Nature Communications, 2016
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP et al.
Oncotarget, 2015
Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.
Sosonkina N et al.
Genes & Genomics, 2014
Select a paper to view details